Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2023 12:00 ET | Source: EF Academy

From the #1 Course at Yale, Happiness Expert Dr. Laurie Santos presents “The Science of Well-Being for Teens” for Los Angeles Parents, Teens and Educators

PASADENA, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- EF Academy, LA’s newest private day and boarding school, today unveils a speaker series focused on Helping Teens Become Successful and Happy....
April 06, 2023 09:30 ET | Source: Klang Games

“The Life Cycle” Podcast from Klang Games Clarifies the Most Important Questions About the Future of Mankind

BERLIN, April 06, 2023 (GLOBE NEWSWIRE) -- Klang Games, the makers behind the sandbox simulation MMO game SEED, are not only concerned with the future of mankind and the colonization of exoplanets...
March 20, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...
March 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...
March 08, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at March Investor Conferences

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
January 19, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
December 19, 2022 07:00 ET | Source: Fuel50

Latest Fuel50 Capability Trends Report Addresses the Impact of Inflation on Organizations & Supports Workforce Agility

LAGUNA NIGUEL, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fuel50, the skills-powered Talent Marketplace solution that delivers internal talent mobility and workforce reskilling, has announced the...
December 15, 2022 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
November 16, 2022 02:12 ET | Source: Proficient Market Insights

Life Reinsurance Market Size In 2022 (New Report) | No. of pages: 115|: Manufacturers Data, Opportunity, Import Export Scenario, Application, Type, Regions and Future Forecast till 2028 with Top Growth Companies

Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Life Reinsurance Market" research report focus on overall information that can help to take decisions on current market situation. Reinsurance, also known as...
November 10, 2022 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...